NCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
Clinical Trials
182 trialsNCT03601078 2026-03-04
KarMMa-2
Celgene
Phase 2 Completed
NCT05283720 2026-03-03
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT06984328 2026-03-03
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Genmab
Phase 2 Active not recruiting
NCT05714345 2026-03-02
EXPAND
Allogene Therapeutics
Phase 2 Terminated
NCT06806033 2026-03-02
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 2 Recruiting
NCT05144841 2026-02-13
MK-2140-004
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT06105632 2026-02-13
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Pfizer
Phase 2 Active not recruiting
NCT05014412 2026-02-10
MagnetisMM-9
Pfizer
Phase 2 Completed
NCT06297226 2026-02-10
QUINTESSENTIAL
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT05126719 2026-02-06
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
Shanghai Miracogen Inc.
Phase 2 Active not recruiting
NCT06485219 2026-02-06
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2 Active not recruiting
NCT06854653 2026-02-03
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
Phase 2 Recruiting
NCT05043922 2026-01-30
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
Haihe Biopharma Co., Ltd.
Phase 2 Active not recruiting
NCT05046314 2026-01-14
A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2 Recruiting
NCT02337829 2026-01-08
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Phase 2 Completed
NCT07312188 2025-12-31
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
Phase 2 Recruiting
NCT06253663 2025-12-16
JKART-1
Gilead Sciences
Phase 2 Active not recruiting
NCT06769698 2025-12-16
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 2 Not yet recruiting
NCT07082686 2025-11-21
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2 Recruiting
NCT07051486 2025-11-17
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
NCT04245839 2025-11-05
TRANSCEND FL
Celgene
Phase 2 Active not recruiting
NCT03568461 2025-10-07
ELARA
Novartis
Phase 2 Completed
NCT05064358 2025-10-07
DREAMM 14
GlaxoSmithKline
Phase 2 Active not recruiting
NCT04447755 2025-10-03
E7080-G000-231
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06534437 2025-09-29
JASPIS-01
Ryvu Therapeutics SA
Phase 2 Recruiting
NCT04191616 2025-09-04
SELECT
Amgen
Phase 2 Completed
NCT02998476 2025-08-22
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Incyte Corporation
Phase 2 Completed
NCT05883449 2025-08-20
LuminICE-203
Affimed GmbH
Phase 2 Terminated
NCT05020015 2025-08-12
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Takeda
Phase 2 Active not recruiting
NCT04684147 2025-08-08
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
Phase 2 Recruiting
NCT02899052 2025-08-05
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
AbbVie
Phase 2 Active not recruiting
NCT04680988 2025-08-05
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT05253807 2025-08-05
FIGHT-210
Incyte Corporation
Phase 2 Completed
NCT07022002 2025-08-03
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2 Recruiting
NCT02986178 2025-07-11
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Phase 2 Completed
NCT04868162 2025-07-08
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Shanghai Miracogen Inc.
Phase 2 Recruiting
NCT03361748 2025-05-23
KarMMa
Celgene
Phase 2 Completed
NCT04176380 2025-05-15
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
Rapa Therapeutics LLC
Phase 2 Completed
NCT05972720 2025-05-15
FIRCE-1
CARGO Therapeutics
Phase 2 Terminated
NCT05275673 2025-04-24
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
Faeth Therapeutics
Phase 2 Terminated
NCT05241093 2025-04-10
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Tarapeutics Science Inc.
Phase 2 Recruiting
NCT06892431 2025-03-25
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Not yet recruiting
NCT03268382 2025-03-17
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
Aprea Therapeutics
Phase 2 Completed
NCT01828021 2025-03-13
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
MacroGenics
Phase 2 Completed
NCT05833724 2025-03-11
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Great Novel Therapeutics Biotech & Medicals Corporation
Phase 2 Recruiting
NCT04868708 2025-03-04
A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
Akeso
Phase 2 Completed
NCT03744676 2025-02-27
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Juno Therapeutics, a Subsidiary of Celgene
Phase 2 Completed
NCT05451810 2025-01-24
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Genmab
Phase 2 Active not recruiting
NCT05263583 2025-01-14
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
Cothera Bioscience, Inc
Phase 2 Active not recruiting